MAA ArTiMist, page-41

Hi Wasa

It wasn't until August 2015 when SUDA bought the final 20% of ArTiMist from PPL that MRC/SUD had full control over the direction and process of getting approval of AirTiMist for pre-referral treatment. In the years since the completion of the favourable trials the approval process was in the hands of PPL when to say the least it was moving at glacial speed. My view is that in the 19 months since taking control the team at SUDA have performed a Herculean task in completing the necessary documentation and submitting the application for marketing approval in March 2017. The team should be congratulated for this achievement and not lamblasted by some at every opportunity. At this time of the year a little good will would make everybodies Christmas lunch much tastier particularly with the prospect/expectation of the marketing approval being granted in the first quarter of 2018 and hopefully being followed up by being included on the WHO essential medicines list.

The outlook for 2018 remains outstanding.

kippax